Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021Business Wire • 10/01/21
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCNBusiness Wire • 09/30/21
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPDBusiness Wire • 09/30/21
Teva Reaches Agreement with Louisiana to Settle the State's Opioid-Related ClaimsBusiness Wire • 09/28/21
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with SchizophreniaBusiness Wire • 08/31/21
Showcasing Teva's Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache.Business Wire • 08/30/21
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive DyskinesiaBusiness Wire • 08/20/21
Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/28/21
Teva Stock Falls After COVID-19 Impacts Q2 Top And Bottomline; Lowers FY21 OutlookBenzinga • 07/28/21